Filter Your Search

Categories

Archive

Case Management: Role of Genetic Evaluation and Testing in Pediatric Hypertrophic Cardiomyopathy
Contributing Author: Stephanie M. Ware, MD, PhD Sep 2016

Pediatric cardiomyopathies are clinically heterogeneous heart muscle disorders (Table 1 see page 4) that cause systolic or diastolic dysfunction and are associated with significant morbidity and mortality. Among affected children, up to 40 percent progress to transplantation or die within five years of diagnosis. Read the full story & the medicine behind it.

CME Credit Form
Case Management: Treatment of Painful Diabetic Neuropathy
Contributing Author: Sidhbh Gallagher, MD Jul 2016

Diabetic neuropathy is a heterogeneous condition that manifests in different clinical forms. Distal symmetric polyneuropathy (DSPN), a process that primarily affects distal peripheral nerves, is the most common form and is often considered synonymous with the term diabetic neuropathy. Painful DSPN occurs in 10 to 26 percent of patients with diabetes and can have a profoundly negative effect on quality of life. Read the full story & the medicine behind it.

CME Credit Form
Case Management: Abdominal Aortic Aneurysm
Contributing Author: Andres Fajardo, MD Jun 2016

AAA is a degenerative process occurring between the diaphragm and the aortic bifurcation that results in a segmental, full-thickness dilatation of the abdominal aorta exceeding the normal vessel diameter by 50 percent (i.e., ≥3.0 cm). AAAs, approximately 85 percent of which are infrarenal, are usually asymptomatic until they rupture, an often fatal event with a mortality of 85 to 90 percent. Of those patients who reach the hospital, only 50 to 70 percent survive. Read the full story & the medicine behind it.

Case Management: Using Precision Medicine to Personalize Cancer Treatment
Contributing Author: Milan Radovich, PhD Dec 2015

ATC is a rare form of undifferentiated cancer that accounts for less than two percent of all thyroid cancers but has a disproportionately high mortality rate of 33 to 50 percent. Patients are usually in their sixth or seventh decade of life at presentation, have an average median survival of five months, and fewer than 20 percent are alive one year after diagnosis. Read the full story & the medicine behind it.